US 11,911,360 B2
Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
Timothy Matthias Morgan, Warrnambool (AU)
Assigned to Lachesis Biosciences Limited, Warrnambool (AU)
Filed by Lachesis Biosciences Limited, Warrnambool (AU)
Filed on Jan. 27, 2021, as Appl. No. 17/160,009.
Application 17/160,009 is a continuation of application No. 16/569,986, filed on Sep. 13, 2019, granted, now 10,933,045.
Application 16/569,986 is a continuation of application No. 15/516,233, granted, now 10,471,040, issued on Nov. 12, 2019, previously published as PCT/AU2015/050591, filed on Sep. 30, 2015.
Claims priority of application No. 2014903944 (AU), filed on Oct. 3, 2014.
Prior Publication US 2021/0145789 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/325 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/32 (2006.01); A61K 31/27 (2006.01); A61K 47/10 (2017.01); A61K 31/13 (2006.01); A61P 25/28 (2006.01); A61P 25/16 (2006.01); A61K 9/08 (2006.01); A61K 31/439 (2006.01); A61K 31/445 (2006.01); A61K 31/485 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/325 (2013.01) [A61K 9/0043 (2013.01); A61K 9/08 (2013.01); A61K 31/13 (2013.01); A61K 31/27 (2013.01); A61K 31/439 (2013.01); A61K 31/445 (2013.01); A61K 31/485 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/32 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01)] 18 Claims
 
1. A sustained-release aqueous intranasal formulation comprising rivastigmine or a pharmaceutically acceptable salt thereof in an amount of from about 0.5% to about 15% by weight of the total formulation, a pH modifying agent and a thickening agent in an amount of from about 0.1% to about 2% by weight of the total composition, wherein pH of the formulation is in the range of about 3 to 6.